Hematologic Malignancies

This article examines clinical and biological features of DLBCL patients with poor outcomes, and reviews recent studies addressing alternatives to standard front-line management strategies together with unresolved questions.
• Identifying Appropriate Patient Groups and Drug Targets in DLBCL
• Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab?

This review addresses the rationale and evidence for—and the challenges, cost implications, and future development of—proton therapy as an important part of the treatment strategy in Hodgkin lymphoma.
• Protons: Moving Therapy for Hodgkin Lymphoma in a Positive Direction
• Proton Radiotherapy: The Good, the Bad, and the Uncertain

The management of leukemias and lymphomas now includes the use of many targeted therapies. Nurses need to have an understanding of the targeted therapies and their side effects so they can appropriately manage the side effects that their patients with leukemias and lymphomas may experience.
• Precision Medicine in the Care of Patients With Leukemia/Lymphoma
• Expanded Treatment Options for Leukemia/Lymphoma

When light-chain amyloidosis is diagnosed prior to the development of advanced cardiomyopathy, systemic therapy is capable of producing hematologic responses that will translate into organ responses and prolonged survival.
• AL Amyloidosis: New Drugs and Tests, but Old Challenges
• AL Amyloidosis: Who, What, When, Why, and Where

In this article, we review the current knowledge on the biological findings, clinical features, and therapeutic approaches for splenic marginal zone lymphoma.
• Splenic Lymphomas: Is There Still a Role for Splenectomy?
• Splenic Marginal Zone Lymphoma: Villous, Not Necessarily Villainous

As an avid gardener, the patient spent considerable time outdoors and had never before experienced a similar problem. However, during the prior two spring-summer seasons. Almost every witnessed mosquito bite resulted in either a swollen, pruritic nodule or a substantial blister. This patient most likely has what underlying disease?

A 58-year-old man developed acute myeloid leukemia. After responding to remission-induction high-dose chemotherapy, he received an allogeneic stem cell transplant that was complicated by a graft-versus-host reaction. While being treated for the latter with prednisone, tacrolimus (Prograf), and mycophenolate mofetil (CellCept), he developed both fungal pneumonia and osteomyelitis caused by Fusarium species.

A 2-year-old girl being treated for acute lymphoblastic leukemia develops a low-grade fever and two hemorrhagic bullae in the groin.

A 63-year-old male was hospitalized following a massive hemorrhage secondary to a motor vehicle accident and subsequent infection of a surgical site. Three weeks post-admittance his WBC demonstrated a marked elevation.

A previously healthy 14-month-old girl presents for evaluation following the gradual appearance and persistence of multiple 4- to 15-mm dome-shaped yellow papulonodules on the scalp, face, and upper trunk.